Using insect cells, scientists in Vienna have developed an alternative method for producing the H1N1 vaccine. The researchers say the discovery, detailed in the Biotechnology Journal, will aid the fight against influenza pandemics by speeding up production and making it easier to meet the demand for vaccines.
"Recent outbreaks of influenza highlight the importance of a rapid and sufficient vaccine supply for pandemic and inter pandemic strains," said co-author Florian Krammer from the University of Natural Resources and Applied Life Science in Vienna. "However, classical manufacturing methods for vaccines fail to satisfy this demand."
Traditional influenza vaccines, which are produced in embryonated chicken eggs, can be manufactured in the quantities needed for seasonal strains of influenza. Yet because of limited egg supply this method may be insufficient in a pandemic scenario, such as the current H1 N1 'swine flu' pandemic.
The team's new method turns to insect cell based technology to create recombinant influenza virus-like particles (VLPs), which resemble virus particles but lack the viral nucleic acid, so they are not infectious.
The Austrian team took just ten weeks to produce swine-origin pandemic H1N1 influenza VLPs for immunological study in mice. This shows that production of a mock-up vaccine is feasible in this time range, outcompeting conventional production methods which take months.
Using insect cells also bypasses the disadvantages of egg-based production, such as limited production capacity, allergic reactions to egg proteins and biosafety issues.
"Our work demonstrates that recombinant influenza virus-like particles are a very fast, safe and efficient alternative to conventional influenza vaccines and represents a significant new approach for newly emerging influenza strains like swine-origin H1N1 or H5N1" concluded Krammer.
"Virus-like particles will be one solution to tackle the biological variability of influenza pandemics," said journal editor Professor Alois Jungbauer. "Mutated strains can be quickly engineered. So in this respect the teams' work is an extremely valuable contribution to modern vaccine production."
Citation: Florian Krammer, Sabine Nakowitsch, Paul Messner, Dieter Palmberger, Boris Ferko, Reingard Grabherr, 'Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice', Biotechnology Journal Online; doi: 10.1002/biot.200900267
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- How A Former Naturopath Can Help Unravel The Trickery of Alternative Medicine
- A Billion Years Ago, What Did Earth's Ancient Magnetic Field Look Like?
- Nanotech: The Most Dangerous Science Least Carefully Done
- Can A New Rule Trigger A Second EU Referendum? Petition Signatures Over 11% Of Total Votes Cast
- Finding All-Hadronic Top - Again
- Insects Were Already Using Camouflage 100 Million Years Ago
- Better Brains With Beer
- "so in a nutshell basically they're not taking worries seriously..."
- "Sentence makes perfect sense. Has it been fixed?..."
- "If its based on signature on rocks, then the hypothesis is wrong. Because rocks form from molten..."
- "You should proof read. The very first sentence makes no sense. Didn't bother reading the rest. ..."
- "Thanks for your understanding!Cheers,T...."
- Got Zika? Thank An Environmentalist
- Magical Moron Moments: Burn Your Feet with Tony Robbins
- IARC is controversial – because they put ideology over science
- Congressman Bob Gibbs: Biotechnology is feeding millions
- Science For the Win: Pepsi Does the Walk of Shame Back to Aspartame
- Help! My Smartwatch Is Nagging Me!
- Patient-centered approach to collect sexual orientation and gender ID information studied
- Cross-respiration between oral bacteria leads to worse infections
- Researchers identify new strategy for decreasing neonatal mortality
- Researcher finds 'ghost workers' common in migrant farm work
- Novel lipid lowering medication improves blood sugar control in type 2 diabetes